Inactive Instrument

Highlights Achieve Life Sciences Inc Nasdaq

Equities

US0044681049

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine	06/05	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting	20/03	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting	11/23/11	CI
Achieve Life Sciences, Inc. Announces Positive Topline Results from A Second Phase 3 ORCA-3 Trial	15/23/15	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association	11/23/11	CI
Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial	23/23/23	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Achieve Life Sciences, Inc. Enters into an Amendment Cooperation Agreement with Dialectic Capital Management, Lp	24/23/24	CI
Achieves Life Sciences, Inc. Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation	08/23/08	CI
Achieve Life Sciences, Inc. Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco Annual Meeting	03/23/03	CI
Achieve Life Sciences, Inc. Announces Last Subject Dosed in Phase 2 Orca-V1 Trial of Cytisinicline for E-Cigarette Cessation	07/23/07	CI
Achieve Life Sciences, Inc. Announces the Final Subject of the Company’s Phase 3 ORCA-3 Trial Has Completed Treatment in the Study	09/23/09	CI
Achieve Life Sciences Receives US Patent for New Formulation of Cytisinicline	21/22/21	MT
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Achieve Life Sciences, Inc. Announces Early Completion of Target Enrollment in Cytisinicline E-Cigarette Cessation Trial	08/22/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Achieve Life Sciences Inc Nasdaq

Equities

US0044681049

Highlights

Filters